Completed PHASE2 INTERVENTIONAL 2-arm NCT00962429

Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study

Sponsor: Collins Medical Trust

Conditions CIDP Chronic Inflammatory Demyelinating Polyneuropathy

Interventions lipoic acid

Updated 9 times since 2017 Last updated: Aug 18, 2020 Started: Feb 28, 2009 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00962429, this PHASE2 trial focuses on CIDP and Chronic Inflammatory Demyelinating Polyneuropathy and remains completed. Sponsored by Collins Medical Trust, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Sep 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2020 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Collins Medical Trust
Oregon Health and Science University

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States